, Tracking Stock Market Picks
Enter Symbol:
Akorn, Inc. (AKRX) [hlAlert]

up 2,024.22 %

Akorn, Inc. (AKRX) rated Outperform with price target $3 by Credit Suisse

Posted on: Thursday,  Feb 26, 2009  8:25 AM ET by Credit Suisse

Credit Suisse rated Outperform Akorn, Inc. (NASDAQ: AKRX) on 02/26/2009, when the stock price was $1.94. Since
then, Akorn, Inc. has gained 2024.23% as of 01/22/2016's recent price of $41.21.
If you would have followed this Credit Suisse's recommendation on AKRX, you would have gained 2024.22% of your investment in 2521 days.

Akorn, Inc. is engaged in manufacturing and marketing diagnostic and therapeutic pharmaceuticals in specialty areas, such as ophthalmology, rheumatology, anesthesia and antidotes, among others. In addition, the Company markets and distributes vaccines purchased from outside sources. Its customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations and other pharmaceutical companies. It has a wholly owned subsidiary named Akorn (New Jersey), Inc., which operates in Somerset, New Jersey and is involved in manufacturing, product development, and administrative activities related to its ophthalmic and hospital drugs & injectables segments. The Company operates in four segments: ophthalmic, hospital drugs & injectables, biologics & vaccines and contract services.

Excellence in equity and fixed income research is a hallmark of Credit Suisse. Globally, our equity research analysts provide in-depth coverage of over 2,500 companies and engage in a knowledge-sharing, value added culture that has yielded the most insightful product for our customers and tremendous competitive results. Additionally, Credit Suisse's powerful macro-economic and debt strategy teams integrate the bank's comprehensive company research with keen market perspectives of the ever-shifting investment terrain.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/26/2009 8:25 AM Buy
1.94 3.00
as of 12/31/2009
1 Week up  180.74 %
1 Month up  224.07 %
3 Months up  283.21 %
1 YTD up  170.61 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy